EGFR and non-small cell lung carcinoma: In our study, early LT improved icPFS, but not OS in EGFR+ and ALK+ NSCLC with BM, regardless of the number of lesions (≤4 versus >4) and the applied technique (WBRT versus SRT, Tables 2 and 3).